Overview

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
This study is a single center, investigator initiated phase II clinical study to evaluate the efficacy and safety of fruquintinib plus Sintilimab as third-line therapy for colorectal cancer
Phase:
Phase 2
Details
Lead Sponsor:
Chinese PLA General Hospital